

#723253

CARDIAC PACING AND ELECTROPHYSIOLOGY TODAY

A New Era of Therapeutic Arrhythmology



APSPPE '93

CARDIAC PACING AND ELECTROPHYSIOLOGY TODAY

A New Era of Therapeutic Arrhythmology

APSPE '93



MAKUHARI JAPAN

Proceedings of the Vth Asian-Pacific Symposium
on Cardiac Pacing and Electrophysiology
1993

© 1993 by the Organizing Committee of the Vth Asian-Pacific
Symposium on Cardiac Pacing and Electrophysiology

All rights reserved

Production assistance by Simul International, Inc., Tokyo, Japan

Printed in Japan

ISBN 4-88329-001-8

CARDIAC PACING AND ELECTROPHYSIOLOGY TODAY

Preface

It is our pleasure to present you with the proceedings of the Vth Asian-Pacific Symposium on Cardiac Pacing and Electrophysiology, entitled "Cardiac Pacing and Electrophysiology Today – A New Era of Therapeutic Arrhythmology." The symposium was held in Makuhari, Japan, from August 1 through 4, 1993. The success of the previous three symposia, in Jerusalem, Melbourne, and Singapore, was the impetus behind our efforts to enlarge the scope of the Vth symposium and to make it truly Asian-Pacific in character.

Reflecting this, a total of more than 1,300 medical scientists and associated professionals participated in the symposium, from thirty-seven countries. The number of presentations was approximately 500, including plenary lectures (Tawara Memorial Lectures), symposia, free papers, luncheon panels, and programs for associated professionals. Due to limited space, only the plenary lectures and the symposia are included in the proceedings.

We believe that these proceedings are the most up-to-date and comprehensive review – from the standpoint of both basic science and clinical application – of cardiac pacing and electrophysiology in 1993, the year which marks the centenary of His' report on the atrioventricular muscular connection in the mammalian heart.

Hiroshi Matsuo

Chair of the Proceedings Committee

Saichi Hosoda

Chair of the Scientific Program Committee

Motokazu Hori

President

Kozo Suma

Chairperson of the Organizing Committee

Toshio Mitsui

Secretary General

Tawara Memorial Lectures	1
(1) Tawara's Contribution to the Discovery of the Conduction System of the Heart <i>K. Suma</i>	3
(2) Future Directions in Cardiac Pacing – Training and Certification <i>J.W. Harthorne</i>	5
(3) Electrical Stimulation of the Heart – Homage to Tawara <i>S. Furman</i>	7
(4) Future Horizons of Cardiac Electrophysiology <i>H.J.J. Wellens</i>	10
I. Present Status of Pacemaker Implantation in Asian-Pacific Rim	13
(1) Cardiac Pacing in China: Present Status and Future Trends <i>Z. Zhu</i>	15
(2) Present Status of Pacemaker Implantation in Asian-Pacific Rim: Indian Experience <i>M. Panja</i>	18
(3) Cardiac Pacing: Indonesian Experience <i>O.J. Rachman</i>	21
(4) The Recent Decade Survey of Cardiac Pacing in Japan <i>T. Mitsui</i>	25
(5) Present Status of Pacemaker Implantation in Asian-Pacific Rim: Korean Experience <i>S.S. Kim</i>	31
(6) Pacemaker Implantation in New Zealand 1992 <i>R.M.L. Whitlock</i>	34
(7) Pacemaker Implantation in South Africa <i>R.N.S. Millar</i>	38
(8) Pattern of Permanent Cardiac Pacing in Sri Lanka <i>P.N. Thenabadu</i>	41
(9) Present Status of Pacing Practices in the Asian-Pacific Rim: The United States of America <i>J.C. Griffin</i>	44
II. Optimal Pacemaker for Individual Patient	47
1) Indications for and Limitations of Physiologic Pacemaker	49
(1) Acute Changes of Left Ventricular Performance During Various Pacings <i>F.M. Zhang</i>	51
(2) Hemodynamic Evaluation of Physiological Pacing <i>S. Tanaka</i>	54
(3) Indication for and Limitations of Physiological Pacemaker <i>Z. Zhu</i>	58
(4) Indications for and Limitations of Physiological Pacemakers <i>U.A. Kaul</i>	61
2) Ideal Sensors of Rate Adaptive Pacemaker	63
(1) The Ideal Sensor for Rate Adaptive Pacing <i>H.G. Mond</i>	65
(2) Ideal Sensors for Rate Adaptive Pacemakers <i>L.S. Dreifus</i>	68
(3) Ideal Sensor of Rate Adaptive Pacemaker: Increase of H ⁺ ions in Venous Blood <i>L. Cammilli</i>	72
(4) Ideal Sensors of Rate Adaptive Pacing <i>A.K. Barooah</i>	76
(5) Ideal Sensors for Rate Adaptive Pacing <i>A.F. Rickards</i>	78
(6) Combined Oxygen Uptake Analysis and Graded Exercise Testing for Evaluation of Rate-adaptive Pacemakers <i>D.G. Benditt</i>	80
(7) Combinations of Sensor Information: How to combine them? <i>T. Sugiura</i>	84
(8) Ideal Sensors for Rate-adaptive Pacemakers <i>M. Schaldach</i>	88

3) How to Choose the Optimal Pacemaker to the Individual Patient	93
(1) How to Choose the Optimal Pacemaker to the Individual Patient <i>D. Huang</i>	95
(2) How to Choose the Optimal Pacemaker to the Individual Patient <i>P.N. Thenabadu</i>	98
(3) How to Choose the Optimal Pacemaker for the Individual Patient <i>N. Strathmore</i>	100
(4) How to Choose the Optimal Pacemaker to Minimize the Occurrence of Pulmonary Embolism After Pacing <i>Y. Matsuura</i>	102
(5) Clinical Features of Patients for Whom Pulse Generator Battery Size and Longevity Is an Important Consideration in Pacemaker Selection <i>D.T. Kawanishi</i>	105
III. Complications and Trouble Shooting	109
1) Pacemaker Syndrome and Hemodynamics	111
(1) The Pacemaker Syndrome and Its Onset Mechanism <i>T. Mitsui</i>	113
(2) Pacemaker Syndrome and Hemodynamics <i>A.K. Barooah</i>	124
(3) Pacemaker Syndrome and Hemodynamics <i>H.B. Trisnohadi</i>	126
(4) Pacemaker Syndrome and Hemodynamics <i>F.A. Pirezada</i>	131
(5) Prognosing the Pacemaker Syndrome After the AV Junction Ablation <i>V.V. Pekarsky</i>	135
(6) Atrial Natriuretic Factor and Pacemaker Syndrome <i>C.O. Pun</i>	138
2) Complications and Trouble Shooting	141
(1) Complications and Trouble Shooting Techniques of Permanent Pacing: Differential Diagnosis and Incidence of Occurrence <i>M. Murase</i>	143
(2) Complications and Trouble Shooting <i>F.A. Pirezada</i>	148
(3) Complications and Trouble-shooting in 84 Patients with Permanent Pacemaker <i>H. Matsuo</i>	156
(4) Recent Ten Years' Experience with Permanent Pacemaker Implantation <i>S. Kawada</i>	161
(5) Intra-operative Analysis During Implantation of Cardiac Pacing Systems – An Associated Professional Perspective <i>M.E. Irwin</i>	164
(6) Problem Solving: How to Read Pacemaker Patient ECGs <i>Y.S. Choi</i>	170
3) Extraction of Chronically Implanted Pacemaker Lead	173
(1) Intravascular Lead Extraction: Technique Tips and US Database Results <i>T.D. Sellers</i>	175
IV. Cost/effectiveness and Reuse of Pacemaker	179
1) Cost/effectiveness of DDD and DDDR	181
(1) Cost Effectiveness of DDD and DDDR Pacing <i>H.G. Mond</i>	183
(2) Cost Effectiveness of DDD/DDDR Pacemakers <i>S. Mazumdar</i>	185
(3) Cost and Effectiveness of DDD(R) Pacing at Green Lane Hospital <i>R.M.L. Whitlock</i>	188

(4) Cost Effectiveness of DDD Pacemakers in Geriatric Patients with Sick Sinus Syndrome	<i>K. Ueda</i>	192
(5) Cost/Effectiveness of DDD and DDDR Pacemaker	<i>Y. Sakurai</i>	194
2) Reuse and Disposal of Pacemakers		197
(1) Reuse of Pacemakers: Economic and Ethical Considerations	<i>R.C.-J. Chiu</i>	199
(2) Reuse and Disposal of Pacemaker: From the Economical Standpoint	<i>M. Yokoyama</i>	202
(3) Re-use & Disposal of Pacemakers	<i>M. Panja</i>	206
(4) Re-use of Pacemakers: Safety and Patient Selection	<i>Ö. Özsaruhan</i>	208
(5) Full Use of Disposal Pacemaker	<i>K. Ihara</i>	211
V. Role of Computer in Pacemaker Practice		215
1) Role of Computer in Pacemaker Practice		217
(1) The Roles of the Computer in Cardiac Pacing	<i>M.Naito</i>	219
(2) Role of Computers in Pacemaker Practice – A Simulation System	<i>Z. Fang</i>	222
(3) The Role of Computers in Pacemaker Practice	<i>N. Strathmore</i>	225
(4) Improved Pacemaker Follow-up Through Newer Computer Applications	<i>D.T. Kawanishi</i>	226
(5) Role of Computer in Pacemaker Patient Follow-up	<i>T. Toyoshima</i>	228
2) Follow-up of Pacemaker Patients and Quality of Life		231
(1) Follow-up of Pacemaker Patient and Quality of Life	<i>A. Dussaut</i>	233
(2) Follow-up and Quality of Life in Patients with Implanted Pacemaker	<i>Z. Chen</i>	235
(3) Follow-up of Pacemaker Patients	<i>K. Steinbach</i>	237
(4) Follow-up of Pacemaker and Quality of Life	<i>A.K. Maity</i>	240
(5) The Quality of Life in Patients with a Permanent Pacemaker	<i>J. Umemura</i>	243
VI. Bradycardia/tachycardia		247
1) Indications of Cardiac Pacing in Brady- and Tachyarrhythmia and the Prognosis		249
(1) Indications of Pacing in Bradyarrhythmias and Its Prognosis	<i>A.K. Maity</i>	251
(2) Permanent Pacing in Patients with AV Block After Acute Myocardial Infarction	<i>D.T. Kawanishi</i>	254
(3) Temporary Pacing in Postoperative Cardiac Patients	<i>A. Furuse</i>	257
(4) Therapeutic Approach to Torsades de Pointes	<i>D. Tzivoni</i>	260
2) Pacing in Sick Sinus Syndrome		263
(1) New Approaches to the Assessment of Sinus Node Function	<i>A.M. Tonkin</i>	265
(2) Clinical Significance of Atrioventricular Junctional Pacemaker Automaticity in Patients with Sinus Nodal Dysfunction	<i>J.L. Lin</i>	268
(3) Atrial Vulnerability in Patients with Sick Sinus Syndrome	<i>K. Yano</i>	270
(4) Atrial Pacing in Patients with Sick Sinus Syndrome	<i>Y. Nakata</i>	273

(5) AAI Pacing in Sick Sinus Syndrome: Philippine Experience	<i>W.T. Chua</i>	277
(6) Pacing in Sick Sinus Syndrome	<i>K.K. Sethi</i>	279
(7) Pacing in Sick Sinus Syndrome – A New Zealand Perspective	<i>H.F. McAlister</i>	282
3) Diagnosis and Management of Syncope		285
(1) Diagnosis and Management of Syncope	<i>U. Kaul</i>	287
(2) Cardiac Syncope in Apparently Normal Children: Diagnosis and Management	<i>K. Koike</i>	290
(3) Diagnosis and Management of Syncope Using Holter Monitoring	<i>T. Yanaga</i>	294
VII. Electrophysiologic Study and Acceptable Alternatives		297
1) Usefulness and Limitations of Electrophysiologic Study for Ventricular Tachycardia		299
(1) Indications and Limitations of Electrophysiological Study (EPS) in Ventricular Tachycardia	<i>T. Bhattacharjee</i>	301
(2) Usefulness and Limitation of Electrophysiologic Study for Ventricular Tachycardia	<i>Y.T. Tai</i>	306
(3) Usefulness and Limitations of Electrophysiologic Study for Ventricular Tachycardia	<i>W.M. Smith</i>	309
(4) Polymorphous Ventricular Tachycardia and Relevant Electrophysiologic Study	<i>W.H. Qi</i>	313
(5) Usefulness and Limitation of Electrophysiological Studies in Patients with Torsades de Pointes	<i>T. Ohe</i>	315
2) Acceptable Alternatives to Invasive Electrophysiologic Study		319
(1) Acceptable Alternatives to Invasive Electrophysiologic Study: Esophageal Electrophysiologic Study and Others	<i>X.Z. Liu</i>	321
(2) Spatial Distribution of Late Potentials in Patients with Sustained Ventricular Tachycardia	<i>K. Shimomura</i>	324
VIII. Catheter Ablation		329
1) Catheter Ablation for Supraventricular Tachycardia		331
(1) The Use of Intracardiac Echocardiography (ICE) Imaging to Guide RF Catheter Ablation	<i>M.D. Lesh</i>	333
(2) Catheter Ablation of Supraventricular Tachycardia	<i>S. Satake</i>	337
(3) Factors Affecting Short and Long Term Success of Fast Pathway Ablation with Graded Use of Radiofrequency Energy	<i>D. Mehta</i>	340
2) Catheter Ablation for WPW Syndrome		345
(1) Catheter Ablation of Accessory Pathway	<i>S.S. Kim</i>	347
(2) Catheter Ablation for WPW Syndrome	<i>D. Wu</i>	349
(3) Radiofrequency Catheter Ablation of Accessory Pathway	<i>S. Ohnishi</i>	352
3) Catheter Ablation for Ventricular Tachycardia		357
(1) Longterm Experience with Endocardial Fulguration in Managing Ventricular Tachycardia After Myocardial Infarction	<i>Y. Nakazato</i>	359

(2) Catheter Ablation for Ventricular Tachycardia – From DC to RF Ablation <i>Y. Aizawa</i>	363
(3) Catheter Ablation for Ventricular Tachycardia – Why Is Its Role Limited? <i>M.J.E. Davis</i>	366
(4) Significance of Underlying Etiology on Catheter Ablation for Ventricular Tachycardia <i>H. Kasanuki</i>	370
IX. Surgical Treatment	375
(1) Surgical Management of Atrial Fibrillation <i>B.C. Chang</i>	377
(2) Selective Surgical Ablation of the Slow Pathway for Atrioventricular Nodal Reentry <i>H.M. Lo</i>	380
(3) Recent Advances in Surgery for Tachyarrhythmias <i>D.C. Johnson</i>	382
(4) Recent Advances of Surgery for Tachyarrhythmias <i>T. Misaki</i>	384
(5) Considerations for the Surgical Treatment of Tachyarrhythmias <i>M. Ikeshita</i>	387
X. Implantable Cardioverter Defibrillator and Sudden Cardiac Death	393
1) Sudden Cardiac Death in Asian-Pacific Rim	395
(1) Sudden Cardiac Death in Asian-Pacific Rim – Epidemiology, Etiology and Prevention, A Chinese Profile <i>H.Z. Chen</i>	397
(2) Sudden Cardiac Death in Asian Pacific Rim – Epidemiology, Etiology, Prevention <i>C.C. Kar</i>	400
(3) Sudden Cardiac Death in Israel <i>S. Feldman</i>	403
(4) Recent Trend of Sudden Death Occurring During A Daily Life Activity in Japan <i>M. Murayama</i>	406
(5) The Cardiac Conduction System in Sudden Cardiac Death <i>S. Ohkawa</i>	409
(6) Sudden Death Survey in Taipei Metropolitan Area <i>C.W. Kong</i>	413
2) Risk Stratification of Sudden Death in Cardiomyopathy	417
(1) Risk Stratification of Sudden Death in Cardiomyopathy <i>W.P. Jiang</i>	419
(2) Occurrence and Prevention of Sudden Death in Cardiomyopathy <i>Y. Sugishita</i>	423
(3) An Approach to Risk Stratification of Arrhythmic Death in Cardiomyopathy <i>P.J. Jordaan</i>	426
3) Clinical Indications for the Use of Implantable Cardioverter Defibrillator	431
(1) AICD <i>T. Guarnieri</i>	433
(2) Clinical Indications for Implantable Cardioverter Defibrillators <i>J.K. Vohra</i>	434
(3) Clinical Indications for the Use of the Implantable Cardioverter Defibrillator <i>M. Ikeshita</i>	437
(4) Should Cryoablation be Combined with Implantable Cardioverter Defibrillator Implantation? <i>Y. Kosakai</i>	443
(5) Patient Acceptance for Implantable Cardioverter/Defibrillator <i>B. Lüderitz</i>	446

(6) Automatic Pharmacological Cardioverter Defibrillator – Investigation in Animals <i>L. Cammilli</i>	449
(7) How Do Cost-effectiveness Considerations and Population Demographics Influence the Global Approach to Prevention of Sudden Death? <i>A.M. Tonkin</i>	453
XI. Antiarrhythmics	457
1) Recent Advances of Antiarrhythmic Drug Therapy – After Cardiac Arrhythmia Suppression Trial	459
(1) Pharmacology of New Antiarrhythmic Drugs – Effects on Canine Ventricular Arrhythmia Models <i>K. Hashimoto</i>	461
(2) After Cardiac Arrhythmia Suppression Trial in China <i>N. Wu</i>	464
(3) Electrophysiologic Mechanism and Therapeutic Efficacy of Intravenous Flecainide in Termination of Paroxysmal Supraventricular Tachycardia <i>D.S. Gambhir</i>	467
(4) A Survey of Antiarrhythmic Drug Treatment After Cardiac Arrhythmia Suppression Trial in Japan – Japanese Antiarrhythmic Drug Long Term Trial – 1. (JALT1) <i>K. Harumi</i>	470
2) Risk and Benefit of Class III Antiarrhythmic Drugs	473
(1) Risks and Benefits of Class III Anti-arrhythmic Drugs <i>K.J. Hellestrand</i>	475
(2) Action of Class III Antiarrhythmic Agents on Cardiac Muscles <i>M. Hiraoka</i>	479
(3) Electrophysiologic Effects and Efficacy of Single Dose Intravenous Versus Chronic Oral Amiodarone in Preventing Recurrence and Reinducibility of AV Nodal Reentrant Tachycardia <i>D.S. Gambhir</i>	482
(4) Benefit and Risk of New Class III Antiarrhythmic Drugs <i>H. Iinuma</i>	485
XII. New Frontiers of Cardiac Pacing	489
1) New Frontiers of Cardiac and Noncardiac Electrical Stimulation and Monitoring ...	491
(1) Dual Chamber Pacing in Hypertrophic Obstructive Cardiomyopathy <i>D.S. Gambhir</i>	493
(2) Multisensor Rate Regulation of Cardiac and Diaphragm Pacing <i>Y. Harada</i>	496
(3) Expected Pacemaker Technologies <i>T. Togawa</i>	499
2) Skeletal Muscle Application for Circulatory Assist	503
(1) The Animal Experimental Study of Latissimus Dorsi Muscle Cardiomyoplasty <i>Z. Shu</i>	505
(2) Skeletal Muscle for Cardiac Assistance <i>H.O. Nakajima</i>	507
(3) Dynamic Cardiomyoplasty: An Overview <i>R. Cecere</i>	511
(4) Dynamic Cardiomyoplasty as a Circulatory Assist <i>M. Okada</i>	513
(5) Electro-cardiac-myostimulation in Patients with Arrhythmias after Cardiomyoplasty of Latissimus Dorsi Muscle <i>V.V. Pekarsky</i>	520

Survey	523
International Advisors	529
Local Organizing Committee	530
Sub-Committees	531
Author Index	533
Subject Index	539

Tawara Memorial Lectures



Sunao Tawara (1873–1952)

Tawara's Contribution to the Discovery of the Conduction System of the Heart

K. Suma

*Dept. of Cardiovascular Surgery, Tokyo Women's Medical College
Daini Hospital, Japan*

Just 100 years ago, that is, in 1893, His reported on the atrioventricular bundle in the human heart. This bundle is now called the bundle of His. Ten years after this monumental year, Tawara went from Japan to Germany to study medicine. Three years later, he published his historic monograph¹, in which he presented the results of the research he conducted in Ludwig Aschoff's laboratory in Marburg. At that time, controversy still existed as to whether the conduction of excitation of the heart is neurogenic or myogenic. However, Tawara used the term "Reizleitungssystem" to describe the specialized myocardial tissue. Reizleitungssystem means stimulus or excitation conduction system.

There are two important words that Tawara was first to use with regards to the specialized myocardial tissue. One is "conduction" and the other is "system". By using the term "conduction", Tawara definitely indicated that the specialized myocardial tissue is responsible for conduction of excitation, that is, that conduction is myogenic. Now, please pay attention to the second term, "system". System means an integrated group of several components that perform a certain function. Prior to Tawara, however, only one component of the conduction system, this is, the atrioventricular bundle of His had been known. Only one component is not a system. Tawara also described two other components. These are the atrioventricular node and the left and right bundle branches. In addition, he identified yet another component, the Purkinje fibers, as the terminal component of the system. Although Purkinje fibers were first described by Purkinje in 1845, their function was not known until Tawara identified them as the termination of the conduction system.

In describing this system, Tawara made good use of analogies. He said that the conduction system is a closed system, like that of a tree. This anatomical tree is rooted in the atrial septum, the stem and the main branches penetrate the fibrous septum and the ventricular septum, their peripheral branches reach the papillary muscles and the parietal walls, and finally the smallest twigs spread as the terminal ramifications of the conduction system. Tawara compared this architecture to those of the respiratory system, the circulatory system and the nervous system. Although those systems have a tree-like architecture, they convey, respectively, gases, fluids and impulses. In a ductal pathway, transportation of gases or fluids takes place. On the other hand, in a parenchymatous pathway, transportation of impulses takes place. Based on his observation that the Reizleitungssystem is parenchymatous, Tawara concluded that the function of this system is to conduct impulses.

Tawara estimated the conduction velocity very accurately. Prior to Tawara's research, the pathway was considered to be very short, because the bundle of His was believed to connect with the ordinary ventricular muscle at the top of the ventricular septum. Because the time interval between the atrial and ventricular contractions, that is, PR interval, is relatively long, and because the pathway is short, Tawara's contemporaries believed that the conduction velocity is slow. However, Tawara discovered that the system extended from the a-v node to the Purkinje fibers, and thus found that the pathway is longer than was believed. He consequently concluded that the velocity must be faster than had been believed. However, from the histological characteristics of the a-v node, he admitted that the node retards conduction.

Tawara said that this characteristic architecture, by which the impulse is transported to the remotest segments of the ventricular wall through closed pathways, serves to convey the excitation impulse as effectively and as simultaneously as possible to all sites of the ventricular wall. For this reason, the velocity of an impulse wave in the connecting bundle must be faster than in ordinary ventricular muscles.

The present-day data reveals that Tawara's estimation was very accurate. Velocity is slow in the a-v node, but is very fast in the His-Purkinje system, being much faster there than in ordinary myocardium.

During the 1970 or 1980, a controversy arose concerning the concept of hemiblock, which had been proposed by a school in Buenos Aires. This concept was based upon an understanding of the left bundle branch as being bifascicular. However, Tawara had many years earlier indicated the left bundle branch as being relatively broad at its origin and spreading like a fan, or as being trifascicular. Our present understanding accords with Tawara's illustration. It is said that if more attention had been paid to Tawara's work, much controversy could have been avoided.

Tawara included several questions and suggestions in his monograph. I will cite two of them. He asked, for instance, "What is the physiological function of the nerve bundles accompanying the conduction system?" He suggested, for instance, that each segment of the system is histologically varied and that each segment performs somewhat different function. Further experimental and physiological studies will clarify what significance each segment has in conducting excitation. Nowadays, these question and suggestion are very important in the understanding the genesis of arrhythmias.

Almost ninety years have passed since Tawara published his monograph. His descriptions and illustrations of the conduction system are so complete and so perfect that it is very difficult to improve on them even today. The monograph is still new and suggestive even now. I wish to conclude my talk with a saying of Confucius, "On-Ko-Chi-Shin" (溫故知新) This means "Exploring the Old, one becomes able to understand the New".

Reference

1. Tawara, S : Das Reizleitungssystem des Säugetierherzens. Eine anatomisch-histologische Studie über das Atrioventrikulärbündel und die Purkinjeschen Fäden. 1906 Verlag von Gustav Fischer in Jena.

Future Directions in Cardiac Pacing – Training and Certification

J.W. Harthorne, M.D.

*Director, Pacemaker Lab, Massachusetts General Hospital
Boston, Massachusetts, USA*

With advancing complexity of pacemaker device hardware and combinations of defibrillators, pacemakers, and multi-sensor technology, the era when implantation technique could be self taught is over. The widespread practice of unskilled, untutored and often unscrupulous physician implanters whose annual procedure rate was often little more than a handful of cases contributed to the public perception of fraud, waste, and abuse in device usage. A proposal has been previously offered¹ to stratify the training of pacemaker physicians into those who prescribe and follow (Track I) and those who also implant devices (Track II). With the growing restriction on third party carrier reimbursement of hospital and professional fees, it is expected that a move toward regionalization of device implantation will occur. So too, declining hospital reimbursement will create more emphasis on regional buying groups and contract purchases.

The optimal plan would be for those who follow either Track I or Track II to obtain their training in a Pacemaker Center of Excellence. Such an institution may be characterized as 1.) performing in excess of 100 procedures annually by 2.) a limited number of implanting physician implanters, each of whom performs a *minimum* of 12 procedures annually. The program will have a recognizable service director who has a predominant commitment to pacing, teaching, and who performs at least 50 device implantations per year and who has the requisite sub-specialty boards in his or her specialty including the NASPE Examination of Special Competency in Pacing. Trainees will follow a prescribed course of instruction as enumerated below and at the conclusion of such training, will be certified by the program director as having successfully completed the course.

Track I

Those who prescribe and follow patients with cardiac pacemakers, but do not implant devices should have a thorough knowledge of cardiac anatomy, electrophysiology, and cardiac pharmacology including the effects of various drugs on the cardiac conduction system. He or she should be familiar with the comparative benefits of available devices as well as the technical nuances of device implantation. They should understand concurrent anatomic and surgical anomalies (i.e. congenital venous anomalies, prosthetic valves, AICD etc.) that may impede or alter device insertion. Finally, they should be comfortable with the use of standard programmers and understand the implications and clinical benefit of such interactions on device performance and longevity.